对他类药物的个体化剂量反应与心血管疾病结局相关
Sachin K Aggarwal1, Lan Jiang2, Ge Liu2
1Vanderbilt University School of Medicine, Nashville, TN, USA.
立方体强度 (ED50) 和疗效 (Emax) 与心血管结果有关. 了解这些剂量反应参数可以帮助个性化他类药物治疗以预防动脉样硬化心血管疾病 (ASCVD).
科学领域:
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
- 数据科学数据科学数据科学
背景情况:
- 类药物有效降低低密度脂蛋白胆固醇 (LDL-C),并预防动脉样硬化心血管疾病 (ASCVD).
- 个体患者对他类药物的反应有所不同,受到基线LDL-C (E0),功效 (ED50) 和最大疗效 (Emax) 的影响.
- 个人化他类药物剂量-反应参数与ASCVD事件风险之间的关系尚不清楚.
研究的目的:
- 分析他类药物强度 (ED50) 和疗效 (Emax) 与真实世界心血管疾病结局之间的关联.
- 调查他类药物的个性化药理性质如何与ASCVD事件和全因死亡率有关.
主要方法:
- 使用了从处方阿托瓦斯塔丁,西姆瓦斯塔丁或罗斯瓦斯塔丁的个人中取消身份的电子健康记录.
- 使用非线性混合效应剂量反应模型对3033名患者获得ED50和Emax.
- 进行了时间到事件分析,以评估ED50,Emax和ASCVD事件和全因死亡率的复合终点之间的关系.
主要成果:
- 估计ED50和Emax对于阿托瓦斯塔丁,西姆瓦斯塔丁和罗斯瓦斯塔丁队列.
- 发现ED50和Emax在不同类型的他类药物中独立与主要终点相关.
- 报告了ED50和Emax的显著危险比率,表明它们对ASCVD风险的影响.
结论:
- 这项研究表明,他类ED50和Emax与临床结果之间存在全类相关性.
- 这些药理参数是接受他类药物治疗的患者中ASCVD事件风险的显著预测因素.
- 个性化剂量反应指标可以告知风险分层和个性化他类药物治疗策略.
更多相关视频
08:45LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Cardiovascular Drugs: Classification based on Therapeutic Indications
